Pathology: MIBC - NA - all population; MIBC - NA - PDL1 positive; mUC - L1 - all population; mUC - L1 - PDL1 positive; mUC - L2 - all population; mUC - L2 - PDL1 positive; mUC - M - all population; mUC - M - PDL1 positive;
MIBC - NA - all population | MIBC - NA - PDL1 positive | mUC - L1 - all population | mUC - L1 - PDL1 positive | mUC - L2 - all population | mUC - L2 - PDL1 positive | mUC - M - all population | mUC - M - PDL1 positive | ||||||||||||
IMvigor-010, 2021 | CheckMate 274 (all population), 2017 | CheckMate 274 (PDL1>1%), 2017 | IMvigor-130 (At-arm B vs Ch-armC), 2020 | IMvigor-130 (At-arm A vs Pl-arm C), 2020 | DANUBE (D vs C - all population), 2020 | DANUBE (DT vs C - all population), 2020 | KEYNOTE-361 (P vs C), 2021 | KEYNOTE-361 (PC vs C), 2021 | DANUBE (D vs C - PDL1>25%), 2020 | DANUBE (DT vs C - PDL1>25%), 2020 | IMvigor-211 (all population), 2018 | KEYNOTE-045 (all population), 2017 | IMvigor-211 (PDL1>5%), 2018 | IMvigor-211 (PDL1>1%), 2018 | KEYNOTE-045 (PDL1 CPS >10%), 2017 | JAVELIN Bladder 100 (all population), 2020 | JAVELIN Bladder 100 (PDL1>25%), 2020 | ||
atezolizumab alone | 5 | T1 | T1 | T1 | T1 | T1 | |||||||||||||
pembrolizumab alone | 3 | T1 | T1 | T1 | |||||||||||||||
durvalumab alone | 2 | T1 | T1 | ||||||||||||||||
durvalumab plus tremelimumab | 2 | T1 | T1 | ||||||||||||||||
avelumab alone | 2 | T1 | T1 | ||||||||||||||||
nivolumab alone | 2 | T1 | T1 | ||||||||||||||||
pembrolizumab plus SoC | 1 | T1 | |||||||||||||||||
atezolizumab plus SoC | 1 | T1 | |||||||||||||||||
no additional treatment | 0 | T0 | |||||||||||||||||
gemcitabine plus platin | 0 | T0 | T0 | T0 | T0 | T0 | T0 | ||||||||||||
placebo plus SoC | 0 | T0 | |||||||||||||||||
BSC | 0 | T0 | T0 | ||||||||||||||||
placebo | 0 | T0 | T0 | ||||||||||||||||
Standard of Care (SoC) | 0 | T0 | T0 | T0 | T0 | T0 | T0 |